[ Price : $8.95]
FDA issues an early alert warning about a potentially high-risk issue involving certain lots of Boston Scientific's ENROUTE Transc...[ Price : $8.95]
FDA cites Bausch + Lomb for GMP deficiencies following a 3/12-20 inspection of the company's sterile drug manufacturing facility i...[ Price : $8.95]
Lilly says its triple hormone receptor agonist retatrutide met the primary weight loss endpoint in two Phase 3 trials.[ Price : $8.95]
Advocacy group Public Citizen files a petition urging FDA to ban prescription drug direct-to-consumer advertising.[ Price : $8.95]
FDA accepts for review Revolution Medicines' NDA for daraxonrasib, an investigational oral RAS-targeted therapy for patients with ...[ Price : $8.95]
Attorney Megan Robertsons analysis of 2026 FDA Warning Letters shows that CDER has been the most active Center, going after telehe...[ Price : $8.95]
FDA releases the form FDA-483 issued following a 2026 inspection at the CSL Behring biological drug manufacturing facility in Marb...[ Price : $8.95]
FDA publishes a strategy document on facilitating chemistry, manufacturing, and controls readiness for products in accelerated dev...